SEC Form 4 · accession 0001178913-18-002082
Foamix Pharmaceuticals Ltd. · FOMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stanley Hirsch
Director
Period of report
Jul 13, 2018
Accepted (ET)
Jul 13, 2018 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001606645
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Jul 13, 2018 | M | 1,616 | $0.00 | A | 12,974 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1,F4,F3 | $0.00 | Jul 13, 2018 | M | 1,616 | D | — | — | Ordinary Shares | 1,616 | 0 | D |
Explanation of responses
- F1This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
- F2The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 6,508 ordinary shares previously reported in Table I of the reporting person's Form 4 (ii) 1,616 ordinary shares underlying restricted share units that vested on July 13, 2018 (iii) 4,850 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security.
- F3The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on July 13, 2018 and 6.25% every three months thereafter) ending July 13, 2021.
- F4This class of restricted share units is included in Column 5 of Table I above.